SARS-CoV-2 Spike glycoprotein Alpha (B.1.1.7) variant trimeric ectodomain from mammalian CHO cells, in glycerol stock
Description: SARS-CoV-2 recombinant Spike Alpha-UK (B.1.1.7) variant (SCoV2-rSα) glycoprotein ectodomain expressed as secreted trimeric protein in mammalian (hamster) CHO cells. It contains nine mutations in comparison to the reference SARS-CoV-2 Spike protein sequence (UniProtKB accession number: P0DTC2 (SPIKE_SARS2)): HV69/70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H; expressed ectodomain includes amino acids (aa) 1-1208. Whole expression construct includes: full-length SCoV2-S ectodomain (aa 1 – 1208) w/o transmembrane and cytoplasmic aa, furin cleavage site “RRAR” mutated to “GSAS”, C-terminal GSN4 trimerization motif fused to protein sequence, then follows thrombin cleavage site, Strep-tag II and His6-tag. Two mutations (K986P and V987P) were introduced into SCoV2-S sequence to stabilize the trimer in the pre-fusion conformation. SCoV2-rSα glycoprotein was purified from culture medium under native (non-denaturing) conditions using convenient chromatographic techniques. Final product is formulated in glycerol stock for long-term storage in liquid form at -20°C.
Form: formulated in glycerol stock solution (50%) in PBS (pH 7.4).
Storage: The product is shipped with dry ice (shipment cost to Europe: 160 €). Store at -20ºC in liquid form (solution does not freeze at this temperature).
Concentration: 0.5 mg/ml.
Purity: >90 % as determined by SDS-PAGE.
Image: SDS-PAGE showing SCoV2-rSα product 21-S2SUK1-TCg-G at approximately 160 kDa (3 μg/lane).
Applications (tested): ELISA, other immunoassays, Western blot, SDS-PAGE.
Quality: According to the expressed construct, purified SCoV2-rSα protein should be trimer in the stabilized prefusion conformation. Full-length trimeric protein enables detection of more antibodies against SCoV2-S, than shorter protein constructs (e.g., RBD or S1). It provides a tool to develop highly sensitive immunoassays. This product 21-S2SUK1-TCg-G showed similar results in ELISA with COVID-19 positive and negative patient sera, as initial sequence SCoV2-rS protein construct (see product 20-S2S-TCg-G information), but a lesser number of individual sera was tested.
|50 μg||21-S2SUK1-TCg-G-L||325 €||
Inquiry / Order
|100 μg||21-S2SUK1-TCg-G-C||500 €|
|500 μg||21-S2SUK1-TCg-G-D||1875 €|
|1 mg||21-S2SUK1-TCg-G-M||3125 €|